Logo

Danish Society for Biopharmaceutical Statistics

Logo

The Danish Society for Biopharmaceutical Statistics (DSBS) was formed in March 1992 as an independent non-profit association. The aims of DSBS are to further the exchange of information between professional statisticians working for the pharmaceutical industry in Denmark and abroad, to promote professional standards, and to constitute an expert body in biopharmaceutical statistical matters. About 150 statisticians, representing 13 companies, are members of the society

Logo


Coming events



Two-part DSBS Course: Survival Analysis in Clinical Trials

Part 1: 17-18 January 2018
Part 2: 31 January - 1 February 2018


Deadline 6 January 2018

Read more in the flyer: Survival Course 2018 Flyer



Recent events



Logo

Draft ICH E9 addendum on
Estimands and Sensitivity Analysis



Monday, 20 November 2017, 15:00 at Lundbeck A/S

DSBS plans to comment on the draft addendum to ICH E9 via EFSPI

Link to guideline: ICH E9 (R1) addendum on estimands and sensitivity analysis


Logo

Presentations from half-day meeting on Estimands
26 Oct 2017



Speaker Presentation as pdf
Agenda Detailed program
Frank Bretz How the ICH E9 addendum around estimands may impact our clinical trials
Søren Andersen & Helle Lynggaard Implementation of estimands in Novo Nordisk
Mette Krog Josiassen Applying estimand strategies in schizophrenia


Logo

Presentations from DSBS 25th Anniversary
31 March 2017



Speaker Presentation as pdf
Agenda Detailed program
Karsten Schmidt, Claus Bay & Merete Jørgensen Biostatistics in the regulatory environment and the formation of DSBS in the 1990’s
Ralf Bender, Institute for Quality and Efficiency in Health Care (IQWiG) Evaluation of subgroup analyses in the framework of benefit assessment
Erik Doffagne, CluePoints Using central statistical monitoring to drive quality into clinical trials
Nedjad Losic, Genmab Two Bayesian designs for first-in-human trials in cancer
Anders Malmberg, Ferring A phase II trial with response-adaptive allocation
Lasse Sluth, Lundbeck and Lars Endahl, Novo Nordisk Regulatory interaction with Asia